- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
[作者:Grothey, A; Sugrue, MM; Purdie, DM; Dong, W; Sargent, D; Hedrick, E; Kozloff, M,期刊:Journal of clinical oncology, 页码:5326-5334 , 文章类型: Article,,卷期:2008年26-33]
- PurposeBevacizumab provides a survival benefit in first- and second-line metastatic colorectal cancer (mCRC). In a large, observational, bevacizumab treatment study (Bevacizumab Regimens: Investigation of Treatment Effec...
- Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases
[作者:Blazer, DG; Kishi, Y; Maru, DM; Kopetz, S; Chun, YS; Overman, MJ; Fogelman, D; Eng, C; Chang, DZ; Wang, H; Zorzi, D; Ribero, D; Ellis, LM; Glover, KY; Wolff, RA; Curley, SA; Abdalla, EK; Vauthey, JN,期刊:Journal of clinical oncology, 页码:5344-5351 , 文章类型: Article,,卷期:2008年26-33]
- PurposeThe primary goal of this study was to evaluate whether pathologic response to chemotherapy predicts patient survival after preoperative chemotherapy and resection of colorectal liver metastases (CLM). The secondar...
- Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
[作者:Wilke, H; Glynne-Jones, R; Thaler, J; Adenis, A; Preusser, P; Aguilar, EA; Aapro, MS; Esser, R; Loos, AH; Siena, S,期刊:Journal of clinical oncology, 页码:5335-5343 , 文章类型: Article,,卷期:2008年26-33]
- PurposeThis large, multinational study aimed to confirm in a community practice setting the efficacy and safety of cetuximab plus irinotecan in patients with epidermal growth factor-expressing metastatic colorectal cance...
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
[作者:Heinrich, MC; Maki, RG; Corless, CL; Antonescu, CR; Harlow, A; Griffith, D; Town, A; McKinley, A; Ou, WB; Fletcher, JA; Fletcher, CDM; Huang, X; Cohen, DP; Baum, CM; Demetri, GD,期刊:Journal of clinical oncology, 页码:5352-5359 , 文章类型: Article,,卷期:2008年26-33]
- PurposeMost gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor alpha (PDGFRA) kinases, which are imatinib targets. Sunitinib, which targets KIT, PDGFRs, and several other...
- Clinically Applicable Models to Characterize BRCA1 and BRCA2 Variants of Uncertain Significance
[作者:Spearman, AD; Sweet, K; Zhou, XP; McLennan, J; Couch, FJ; Toland, AE,期刊:Journal of clinical oncology, 页码:5393-5400 , 文章类型: Article,,卷期:2008年26-33]
- PurposeTwenty percent of individuals with a strong family and/or personal history of breast and ovarian cancer carry a deleterious mutation in BRCA1 or BRCA2. Identification of mutations in these genes is extremely benef...
- Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
[作者:Inoue, A; Sugawara, S; Yamazaki, K; Maemondo, M; Suzuki, T; Gomi, K; Takanashi, S; Inoue, C; Inage, M; Yokouchi, H; Watanabe, H; Tsukamoto, T; Saijo, Y; Ishimoto, O; Hommura, F; Nukiwa, T,期刊:Journal of clinical oncology, 页码:5401-5406 , 文章类型: Article,,卷期:2008年26-33]
- PurposeAmrubicin, a new anthracycline agent, and topotecan are both active for previously treated small-cell lung cancer (SCLC). No comparative study of these agents has been reported. This randomized phase II study was ...
- Positron Emission Tomography/Computed Tomography in the Diagnosis of Multifocal Primary Hepatic Lymphoma
[作者:Chan, WKS; Tse, EWC; Fan, YS; Zhang, JB; Kwong, YL; Khong, PL,期刊:Journal of clinical oncology, 页码:5479-5480 , 文章类型: Editorial Material,,卷期:2008年26-33]
-
|